journal
MENU ▼
Read by QxMD icon Read
search

Journal of Prevention of Alzheimer's Disease

journal
https://www.readbyqxmd.com/read/30298187/supplement-11th-conference-clinical-trials-alzheimer-s-disease-october-24-27-2018-barcelona-spain-posters-late-breaking-news
#1
(no author information available yet)
No abstract text is available yet for this article.
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/30298186/supplement-11th-conference-clinical-trials-alzheimer-s-disease-october-24-27-2018-barcelona-spain-symposia-oral-communications-late-breaking-news
#2
(no author information available yet)
No abstract text is available yet for this article.
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/30298185/letter-to-the-editor-preventing-dementia-through-community-involvement-and-altruistic-behaviors
#3
Y Maki
No abstract text is available yet for this article.
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/30298184/pimavanserin-potential-treatment-for-dementia-related-psychosis
#4
J Cummings, C Ballard, P Tariot, R Owen, E Foff, J Youakim, J Norton, S Stankovic
Psychosis is common across dementia types with a prevalence of 20% to 70%. Currently, no pharmacologic treatment is approved for dementia-related psychosis. Atypical antipsychotics are frequently used to treat these disorders, despite significant safety concerns. Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, was approved in the U.S. for treating hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Patients in the pimavanserin group experienced a significant (p=0.001) improvement in Scale for the Assessment of Positive Symptoms - Parkinson's disease (SAPS-PD) scores vs...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/30298183/clinical-application-of-apoe-in-alzheimer-s-prevention-a-precision-medicine-approach
#5
C L Berkowitz, L Mosconi, A Rahman, O Scheyer, H Hristov, R S Isaacson
Population-attributable risk models estimate that up to one-third of Alzheimer's disease (AD) cases may be preventable through risk factor modification. The field of AD prevention has largely focused on addressing these factors through universal risk reduction strategies for the general population. However, targeting these strategies in a clinical precision medicine fashion, including the use of genetic risk factors, allows for potentially greater impact on AD risk reduction. Apolipoprotein E (APOE), and specifically the APOE ε4 variant, is one of the most well-established genetic influencers on late-onset AD risk...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/30298182/psychometric-evaluation-of-the-neuropsychological-test-battery-in-individuals-with-normal-cognition-mild-cognitive-impairment-or-mild-to-moderate-alzheimer-s-disease-results-from-a-longitudinal-study
#6
J E Harrison, D M Rentz, H R Brashear, H M Arrighi, M T Ropacki, E Liu
BACKGROUND: The Neuropsychological Test Battery (NTB) is a combination of widely used clinical neuropsychological tests measuring memory and executive function and was designed to overcome some of the limitations of the traditionally used Alzheimer's disease Assessment Scale - Cognitive subscale (ADAS-Cog). A previously reported account indicated high levels of NTB reliability in patients with mild-to-moderate Alzheimer's disease (AD) and mild cognitive impairment (MCI). OBJECTIVES: We examined capacity of the Neuropsychological Test Battery (NTB) and its component subtests to measure cognitive change over time...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/30298181/geographic-clusters-of-alzheimer-s-disease-mortality-rates-in-the-usa-2008-2012
#7
R W Amin, E M Yacko, R P Guttmann
IMPORTANCE: The results identified geographic clusters of high and low Alzheimer's disease (AD)-related mortality across the contiguous United States. These clusters identify specific geographic groupings of counties that allow researchers to narrow the focus to identify some of the biopsychosocial variables contributing to increased or decreased AD mortality. OBJECTIVES: To determine the extent to which geographic clusters exist where AD mortality significantly differs from the national average...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/30298180/female-sex-and-alzheimer-s-risk-the-menopause-connection
#8
O Scheyer, A Rahman, H Hristov, C Berkowitz, R S Isaacson, R Diaz Brinton, L Mosconi
Along with advanced age and apolipoprotein E (APOE)-4 genotype, female sex is a major risk factor for developing late-onset Alzheimer's disease (AD). Considering that AD pathology begins decades prior to clinical symptoms, the higher risk in women cannot simply be accounted for by their greater longevity as compared to men. Recent investigation into sex-specific pathophysiological mechanisms behind AD risk has implicated the menopause transition (MT), a midlife neuroendocrine transition state unique to females...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/30298179/assessment-of-instrumental-activities-of-daily-living-in-older-adults-with-subjective-cognitive-decline-using-the-virtual-reality-functional-capacity-assessment-tool-vrfcat
#9
A S Atkins, A Khan, D Ulshen, A Vaughan, D Balentin, H Dickerson, L E Liharska, B Plassman, K Welsh-Bohmer, R S E Keefe
BACKGROUND: Continuing advances in the understanding of Alzheimer's disease progression have inspired development of disease-modifying therapeutics intended for use in preclinical populations. However, identification of clinically meaningful cognitive and functional outcomes for individuals who are, by definition, asymptomatic remains a significant challenge. Clinical trials for prevention and early intervention require measures with increased sensitivity to subtle deficits in instrumental activities of daily living (IADL) that comprise the first functional declines in prodromal disease...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/30298178/what-we-learn-from-the-ctad-clinical-trials-alzheimer-s-disease-2018
#10
B Vellas, P Aisen, M Weiner, J Touchon
No abstract text is available yet for this article.
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972215/an-action-plan-to-face-the-challenge-of-dementia-international-statement-on-dementia-from-iap-for-health
#11
H Chertkow
An international committee set up through the IAP for Health met to develop an action plan for dementia. Comprehensive international and national initiatives should move forward with calls for action that include increased public awareness regarding brain health and dementia, support for a broad range of dementia research objectives, and investment in national health care systems to ensure timely competent person-centred care for individuals with dementia. The elements of such action plans should include: 1) Development of national plans including assessment of relevant lifecourse risk and protective factors; 2) Increased investments in national research programs on dementia with approximately 1% of the national annual cost of the disease invested; 3) Allocating funds to support a broad range of biomedical, clinical, and health service and systems research; 4) Institution of risk reduction strategies; 5) Building the required trained workforce (health care workers, teachers, and others) to deal with the dementia crisis; 6) Ensuring that it is possible to live well with dementia; and 7) Ensuring that all have access to prevention programs, care, and supportive living environments...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972214/correlation-of-csf-and-mri-biomarkers-and-progression-of-cognitive-decline-in-an-open-label-mci-trial
#12
L K Joachim, L Frölich, E Rüther, J Wiltfang, W Maier, J Kornhuber, C Bauer, I Heuser, O Peters
In several randomized controlled trials (RCT) acetylcholinesterase-inhibitors (AChE-I) were tested in patients with mild cognitive impairment (MCI) but were ineffective in delaying disease progression as determined by neuropsychological testing only. Here we present data from an open label observational extension of a multicenter RCT in order to assess if biomarkers are providing useful additional information about a drug's efficacy. We followed 83 amnestic MCI patients and performed correlational analyses of Aβ 1-42 and total-Tau in the cerebrospinal fluid (CSF), hippocampal and amygdala volume at baseline, the total duration of blinded and open label AChE-I treatment and the outcome 24 months after inclusion into the RCT...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972213/auraptene-in-the-peels-of-citrus-kawachiensis-kawachibankan-contributes-to-the-preservation-of-cognitive-function-a-randomized-placebo-controlled-double-blind-study-in-healthy-volunteers
#13
M Igase, Y Okada, M Ochi, K Igase, H Ochi, S Okuyama, Y Furukawa, Y Ohyagi
OBJECTIVES: Dementia, which is characterized by a progressive decline in cognitive function, is a major concern in aging societies. Although a number of treatments have been approved, an effective therapy to prevent the disorder is lacking. A supplement that improves cognitive function would benefit patients. The aim of this study was to assess whether auraptene, a citrus coumarin, has a protective effect on cognitive decline. DESIGN: A randomized, placebo-controlled, double-blind study SETTING: Outpatient medical check-up program for cognitive disorders PARTICIPANTS: 84 adult volunteers (they are cognitively normal) met inclusion and exclusion criteria to participate...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972212/detection-of-rater-errors-on-cognitive-instruments-in-a-clinical-trial-setting
#14
D J Connor, C W Jenkins, D Carpenter, R Crean, P Perera
OBJECTIVES: This study examines errors committed by raters in a clinical trial of a memory enhancement compound. BACKGROUND: Findings of clinical trials are directly dependent on the quality of the data obtained but there is little literature on rates or nature of rater errors on cognitive instruments in a multi-site setting. DESIGN: Double-blind placebo-controlled study. SETTING: 21 clinical sites in North America. PARTICIPANTS: Two hundred seventy-five participants...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972211/analysis-of-the-relationship-of-cognitive-impairment-and-functional-impairment-in-mild-alzheimer-s-disease-in-expedition-3
#15
H Liu-Seifert, E Siemers, K Sundell, M Mynderse, J Cummings, R Mohs, P Aisen
BACKGROUND: Clinical progression of Alzheimer's disease is characterized by impairment in cognition and function. OBJECTIVE: To assess the relationship between cognitive and functional impairment in mild Alzheimer's disease. DESIGN: Spearman's rank correlations between cognitive and functional measures were calculated. Autoregressive cross-lagged panel analyses were used to determine the temporal relationship between cognitive and functional decline...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972210/effects-of-a-six-month-multi-ingredient-nutrition-supplement-intervention-of-omega-3-polyunsaturated-fatty-acids-vitamin-d-resveratrol-and-whey-protein-on-cognitive-function-in-older-adults-a-randomised-double-blind-controlled-trial
#16
C Moran, A Scotto di Palumbo, J Bramham, A Moran, B Rooney, G De Vito, B Egan
OBJECTIVES: To investigate the impact of a six-month multi-ingredient nutrition supplement intervention (Smartfish®), containing omega-3 polyunsaturated fatty acids (PUFAs), vitamin D, resveratrol, and whey protein, on cognitive function in Irish older adults. DESIGN: Double-blind, randomised controlled trial (ClinicalTrials.gov: NCT02001831). A quantitative, mixed-model design was employed in which the dependent variable (cognitive function) was analysed with a between-subjects factor of group (placebo, intervention) and within-subjects factor of testing occasion (baseline, three-months, six-months)...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972209/what-have-we-learned-from-expedition-iii-and-epoch-trials-perspective-of-the-ctad-task-force
#17
P S Aisen, E Siemers, D Michelson, S Salloway, C Sampaio, M C Carrillo, R Sperling, R Doody, P Scheltens, R Bateman, M Weiner, B Vellas
Although the results were disappointing from two recent clinical trials of amyloid-targeting drugs in mild-to-moderate AD, the trials provided information that will be important for future studies, according to the EU-US CTAD Task Force, which met in November 2017 to discuss the EXPEDITION3 and EPOCH trials. These trials tested two of the predominant drug development strategies for AD: amyloid immunotherapy and BACE inhibition in populations largely composed of mild AD dementia patients. The results of these trials support the emerging consensus that effective amyloid-targeted treatment will require intervention in early, even pre-symptomatic stages of the disease...
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972208/commentary-fatty-acids-and-alzheimer-s-disease-evidence-on-cognition-and-cortical-%C3%AE-amyloid-from-secondary-analyses-of-the-multidomain-alzheimer-preventive-trial
#18
C Hooper, B Vellas
No abstract text is available yet for this article.
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972207/editorial-who-guidelines-on-community-level-interventions-to-manage-declines-in-intrinsic-capacity-the-road-for-preventing-cognitive-declines-in-older-age
#19
B Vellas, D Scrase, G A Rosenberg, S Andrieu, I Araujo de Carvalho, L T Middleton
No abstract text is available yet for this article.
2018: Journal of Prevention of Alzheimer's Disease
https://www.readbyqxmd.com/read/29972206/editorial-turning-point-towards-blood-biomarker-guided-targeted-therapy-for-precision-medicine-in-alzheimer-s-disease
#20
H Hampel, A Vergallo, U Bonuccelli, S Lista
No abstract text is available yet for this article.
2018: Journal of Prevention of Alzheimer's Disease
journal
journal
48972
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"